Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GPRC5D-CAR-T
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Oricell Announces FDA Clearance of IND for OriCAR-017 CAR-T Cell Therapy for MM
Details : OriCAR-017 (GPRC5D-CAR-T) is a novel GPRC5D targeted CAR-T cell therapy which is being evaluated in phase 1/2 clinical trials for the treatment of relapsed/refractory multiple myeloma.
Product Name : OriCAR-017
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 29, 2024
Lead Product(s) : GPRC5D-CAR-T
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GPRC5D-CAR-T
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact
Details : OriCAR-017, a cutting-edge CAR-T cell therapy targeting GPRC5D to combat relapsed or refractory multiple myeloma, received the green light for its Investigational New Drug (IND) application.
Product Name : OriCAR-017
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 08, 2023
Lead Product(s) : GPRC5D-CAR-T
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GPRC5D-CAR-T
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : RTW Investments
Deal Size : $45.0 million
Deal Type : Series B Financing
Oricell Closes $45M Series B1 Financing to Expand Development of Key Products
Details : With the funding, the Company is now well-positioned to expand its products to the U.S., specifically OriCAR-017, a GPRC5D CAR-T therapeutic that treats relapsed and refractory multiple myeloma, which is a product currently on the stage of IND enabling b...
Product Name : OriCAR-017
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 28, 2023
Lead Product(s) : GPRC5D-CAR-T
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : RTW Investments
Deal Size : $45.0 million
Deal Type : Series B Financing
Details : OriCAR-017 (GPRC5D-CAR-T) developed by Oricell based on the company’s two proprietary technology platforms OriAb and OriCAR, is a GPRC5D-targeted CAR T-Cell therapy used to treat relapsed/refractory multiple myeloma (RRMM).
Product Name : OriCAR-017
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 31, 2023
Details : OriCAR-017 was administered by a single infusion at 3 dose cohorts to 9 patients. In all patients, majority of AEs were transient, manageable, and reversible. CRS only in Grade 1or2. No DLT, Neurotoxicities been observed.
Product Name : OriCAR-017
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 27, 2022
Details : Single infusion of ORICAR-017 (GPRC5D-CAR-T) demonstrates an early, deep and durable responses at all dose levels in heavily pretreated RRMM patients, including patients who relapsed from BCMA CAR-T therapy.
Product Name : OriCAR-017
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 06, 2022
Details : The new funding will go toward the development of OriCell's cell therapy pipeline including Ori-C101, and Company's proprietary discovery platform, as well as the construction of manufacturing plant for both clinical and commercial purpose.
Product Name : Ori-C101
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 08, 2022
Reset All
